ARTICLE | Company News
Catalent, Triphase deal
October 10, 2016 7:00 AM UTC
Catalent granted Triphase exclusive, worldwide rights to cancer candidate CD22-4AP. Catalent will receive an upfront payment and is eligible for development and commercialization milestones, plus roy...